Showing 251-260 of 10218 results for "".
Alma Lasers Soprano ICE
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/alma-lasers-soprano-ice/19242/Soprano ICE is the next generation hair removal laser from Alma Lasers. With Alma Lasers' patented SHR technology, the new ICE offers pain free hair removal.How Do You Compare? Financial Benchmarking Survey Measures Aesthetic Market
https://practicaldermatology.com/topics/practice-management/how-do-you-compare-financial-benchmarking-survey-measures-aesthetic-market/23002/Results of an annual benchmarking survey among medical aesthetic, dermatology, and medispa practices across the US.Dr. Simpson Highlights Potentially Remittive Anti-OX40s at Maui Derm
https://practicaldermatology.com/programs/practical-dermatology/dr-simpson-highlights-potentially-remittive-anti-ox40s-at-maui-derm/32920/Two anti-OX40 drugs in the pipeline may have remittive properties for atopic dermatitis, according to Eric Simpson, MD.SDPA: Medical Director Dr. Hilary Baldwin Discusses Acne and Keloids Lectures
https://practicaldermatology.com/conferences/sdpa-2024/sdpa-medical-director-dr-hilary-baldwin-discusses-acne-and-keloids-lectures/29508/At the SDPA 22nd Annual Fall Dermatology Conference, Practical Dermatology caught up with conference medical director Hilary Baldwin, MD. She explains the key takeaways of her lectures on acne and keloids.FDA Approves Bimzelx for Hidradenitis Suppurativa
https://practicaldermatology.com/series/dermwire-tv/fda-approves-bimzelx-hidradenitis-suppurativa/29518/In this week's DermwireTV, the FDA approves a new treatment for moderate to severe hidradenitis suppurativa; the FDA agrees to review the resubmission of Dupixent for the treatment of CSU; and the president of Merz Aesthetics, North America, joins us to discuss trends in the aesthetic market.SDPA: Dr. Matthew Zirwas Discusses Benefits of Attending the Annual Conference
https://practicaldermatology.com/conferences/sdpa-2024/sdpa-dr-matthew-zirwas-discusses-benefits-of-attending-the-annual-conference/29510/At the SDPA 22nd Annual Fall Dermatology Conference, Practical Dermatology caught up with Matthew Zirwas, MD. Dr. Zirwas shares why he looks forward to lecturing at the annual meeting.Skin Checks and Patient Education on Actinic Keratoses
https://practicaldermatology.com/topics/skin-cancer-photoprotection/skin-checks-and-patient-education-on-actinic-keratoses/20132/During skin checks, it's important for dermatologists to educate patients, especially younger ones, about the extent of sun damage and the benefits of field treatments. Anthony Rossi, MD and Vishal Patel, MD discuss their approaches.AI is Transforming Google. What’s it Mean for Your SEO Strategy?
https://practicaldermatology.com/topics/practice-management/ai-is-transforming-google-whats-it-mean-for-your-seo-strategy/23674/Quality content remains important as Google search algorithms become better able to “think” about search queries.Acne Treatment Strategies
https://practicaldermatology.com/conferences/maui-derm-2022/acne-treatment-strategies/20046/Guy F. Webster, MD, PhD shares acne management strategies that are effective for patients and help minimize use of antibiotics. He also discusses the continued role for isotretinoin for the right candidates.DermWireTV: Pfizer, AbbVie JAKs for AD; Spray-on-Skin; Lubriderm Scholarships
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-pfizer-abbvie-jaks-for-ad-spray-on-skin-lubriderm-scholarships/20043/For the treatment of refractory moderate-to-severe atopic dermatitis, FDA has approved Pfizer’s Cibinqo (abrocitinib) for adults and AbbVie’s Rinvoq (upadacitinib) for patients 12 and older. Researchers at the Houston Methodist Research Institute have paired their patented RNA technologies with Avit